Suppr超能文献

含脱氢-β-脯氨酸的α4β1整合素拮抗剂:配体-受体相互作用中的立体化学识别

Dehydro-β-proline Containing α4β1 Integrin Antagonists: Stereochemical Recognition in Ligand-Receptor Interplay.

作者信息

Tolomelli Alessandra, Baiula Monica, Viola Angelo, Ferrazzano Lucia, Gentilucci Luca, Dattoli Samantha Deianira, Spampinato Santi, Juaristi Eusebio, Escudero Margarita

机构信息

Department of Chemistry "G. Ciamician", University of Bologna , Via Selmi 2, 40126 Bologna, Italy.

Department of Pharmacy and Biotechnology, University of Bologna , Via Irnerio 48, 40126 Bologna, Italy.

出版信息

ACS Med Chem Lett. 2015 May 5;6(6):701-6. doi: 10.1021/acsmedchemlett.5b00125. eCollection 2015 Jun 11.

Abstract

A novel class of dehydro-β-proline-containing peptidomimetics, designed to be effective as α4β1 integrin ligands, has been developed on the basis of the fundamental requirements for the interactions of these transmembrane receptors with bioactive ligands. Dehydro-β-proline ring has been synthesized through an original pathway, involving ring closing metathesis of a diallylamino derivative. The synthesized products showed to be effective and selective as α4β1 integrin antagonists and displayed IC50 values in the nanomolar range in cell adhesion inhibition assays and in VCAM-1-induced phosphorylation of extracellular-signal-regulated kinases. Significant activity was observed also toward the homologous integrin α4β7, while they did not display any activity toward selected members of β1, β2, and β3 families. A strong dependence on the stereochemistry of the heterocyclic central core could be observed. The great importance of α4β1 integrin in chronic inflammatory and autoimmune diseases suggests a possible exploitation of these ligands as lead compounds for therapeutic tools development.

摘要

基于这些跨膜受体与生物活性配体相互作用的基本要求,已开发出一类新型的含脱氢-β-脯氨酸的拟肽,设计用作α4β1整合素配体。脱氢-β-脯氨酸环是通过一条原始途径合成的,该途径涉及二烯丙基氨基衍生物的闭环复分解反应。合成产物显示出作为α4β1整合素拮抗剂有效且具有选择性,并且在细胞黏附抑制试验以及VCAM-1诱导的细胞外信号调节激酶磷酸化试验中,其IC50值处于纳摩尔范围内。对同源整合素α4β7也观察到显著活性,而它们对β1、β2和β3家族的选定成员没有显示任何活性。可以观察到对杂环中心核的立体化学有很强的依赖性。α4β1整合素在慢性炎症和自身免疫性疾病中的重要性表明,这些配体有可能被用作开发治疗工具的先导化合物。

相似文献

1
Dehydro-β-proline Containing α4β1 Integrin Antagonists: Stereochemical Recognition in Ligand-Receptor Interplay.
ACS Med Chem Lett. 2015 May 5;6(6):701-6. doi: 10.1021/acsmedchemlett.5b00125. eCollection 2015 Jun 11.
5
Modulation of αvβ₃- and α₅β₁-integrin-mediated adhesion by dehydro-β-amino acids containing peptidomimetics.
Eur J Med Chem. 2013 Aug;66:258-68. doi: 10.1016/j.ejmech.2013.05.050. Epub 2013 Jun 12.
7
Development of isoxazoline-containing peptidomimetics as dual αvβ3 and α5β1 integrin ligands.
ChemMedChem. 2011 Dec 9;6(12):2264-72. doi: 10.1002/cmdc.201100372. Epub 2011 Sep 26.

引用本文的文献

6
Leukocyte Integrin Antagonists as a Novel Option to Treat Dry Age-Related Macular Degeneration.
Front Pharmacol. 2021 Jan 29;11:617836. doi: 10.3389/fphar.2020.617836. eCollection 2020.
7
Integrin-Targeting Peptides for the Design of Functional Cell-Responsive Biomaterials.
Biomedicines. 2020 Aug 25;8(9):307. doi: 10.3390/biomedicines8090307.
9
Novel Ligands Targeting αβ Integrin: Therapeutic Applications and Perspectives.
Front Chem. 2019 Jul 9;7:489. doi: 10.3389/fchem.2019.00489. eCollection 2019.

本文引用的文献

2
Leukocyte integrins: role in leukocyte recruitment and as therapeutic targets in inflammatory disease.
Pharmacol Ther. 2015 Mar;147:123-135. doi: 10.1016/j.pharmthera.2014.11.008. Epub 2014 Nov 14.
4
Role of integrin alpha4 in drug resistance of leukemia.
Front Oncol. 2014 May 23;4:99. doi: 10.3389/fonc.2014.00099. eCollection 2014.
5
Synthesis and assay of retro-α4β1 integrin-targeting motifs.
Eur J Med Chem. 2014 Feb 12;73:225-32. doi: 10.1016/j.ejmech.2013.12.009. Epub 2013 Dec 19.
6
IL-18 regulates melanoma VLA-4 integrin activation through a Hierarchized sequence of inflammatory factors.
J Invest Dermatol. 2014 Feb;134(2):470-480. doi: 10.1038/jid.2013.342. Epub 2013 Aug 12.
7
Natalizumab: a review of its use in the management of relapsing-remitting multiple sclerosis.
Drugs. 2013 Sep;73(13):1463-81. doi: 10.1007/s40265-013-0102-7.
8
Orally available and efficacious α4β1/α4β7 integrin inhibitors.
Bioorg Med Chem Lett. 2013 Aug 1;23(15):4370-3. doi: 10.1016/j.bmcl.2013.05.076. Epub 2013 May 31.
9
Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center.
Inflamm Bowel Dis. 2013 Mar;19(3):621-6. doi: 10.1097/MIB.0b013e31827eea78.
10
Synthesis and evaluation of 4,5-dihydro-5-methylisoxazolin-5-carboxamide derivatives as VLA-4 antagonists.
Bioorg Med Chem Lett. 2013 Mar 1;23(5):1482-5. doi: 10.1016/j.bmcl.2012.12.043. Epub 2012 Dec 21.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验